August 2018 FDA Recall Drug by Mckesson Corporation
D-1172-2018 - Supterpotent Drug
This Class II drug recall was voluntarily initiated by Mckesson Corporation on August 14, 2018 for the product Drug. The FDA reported the reason for recall as supterpotent drug. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1172-2018
Supterpotent Drug
08-14-2018
09-12-2018
1531 cartons
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Mckesson Corporation
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide within the United States
11-25-2020
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Megestrol Acetate Oral Suspension, USP 400 mg/mL, 10 mL (10 mL UD cups in boxes of 20 cups), Rx Only, Mfg. By: Par Pharmaceutical One Ram Ridge Rd Chestnut Ridge, NY 10977 Dist. By: McKesson Packaging Services a business unit of McKesson Corporation 7101 Weddington Rd. Concord, NC 28027, NDC 63739-549-51
Batch or Lot Expiration Information
Lot# : 0116158 Exp. 4/30/19; 0113903, 0113902, 0113901, Exp. 8/31/18